Effect of Carnitine on Uremic Cardiomyopathy
NCT02322697
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Disorder of Fatty Acid Metabolism
Interventions
DRUG:
Intravenous administration of L-carnitine
Sponsor
Toujinkai Hospital